Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa.

Ohwada R, Hotta M, Sato K, Shibasaki T, Takano K.

Endocr J. 2007 Dec;54(6):953-9. Epub 2007 Nov 12.

2.

Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.

Muñoz-Calvo MT, Barrios V, García de Alvaro MT, Lefort M, Méndez-Dávila C, Argente J, de la Piedra C.

Scand J Clin Lab Invest. 2007;67(4):387-93.

PMID:
17558893
3.

RANKL/RANK/OPG system and bone status in females with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.

Bone. 2012 Jan;50(1):156-60. doi: 10.1016/j.bone.2011.09.054. Epub 2011 Oct 6.

PMID:
22001124
4.

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.

Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.

Osteoporos Int. 2008 Feb;19(2):221-6. Epub 2007 Aug 17.

PMID:
17703270
5.

Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.

Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.

Metabolism. 2007 May;56(5):699-707.

PMID:
17445547
6.

Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.

Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.

Maturitas. 2013 Apr;74(4):363-8. doi: 10.1016/j.maturitas.2013.01.005. Epub 2013 Feb 4.

PMID:
23391500
7.

Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Marek B, Świętochowska E, Kajdaniuk D, Strzelczyk J, Cieślicka A, Wołkowska-Pokrywa K, Kos-Kudła B.

Endokrynol Pol. 2015;66(4):313-21. doi: 10.5603/EP.2015.0040.

8.

Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.

Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.

Ther Apher Dial. 2009 Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x.

PMID:
19379170
9.

Serum osteoprotegerin in adolescent girls with anorexia nervosa.

Misra M, Soyka LA, Miller KK, Herzog DB, Grinspoon S, De Chen D, Neubauer G, Klibanski A.

J Clin Endocrinol Metab. 2003 Aug;88(8):3816-22.

PMID:
12915674
10.

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.

Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G, Avramidis A.

Eur J Endocrinol. 2008 Mar;158(3):411-5. doi: 10.1530/EJE-07-0528.

PMID:
18299476
11.

Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.

Shaarawy M, Fathy SA, Mehany NL, Hindy OW.

Clin Chem Lab Med. 2007;45(11):1498-503.

PMID:
17970704
12.

 Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Wołkowska-Pokrywa K.

Postepy Hig Med Dosw (Online). 2012 Sep 12;66:655-62.

13.

Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.

Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T.

Adv Med Sci. 2013;58(2):338-43. doi: 10.2478/ams-2013-0011.

PMID:
24277958
14.
15.

Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.

Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.

Bone. 2006 Dec;39(6):1352-60. Epub 2006 Aug 14.

PMID:
16905375
16.

Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.

Grigorie D, Neacşu E, Marinescu M, Popa O.

Rom J Intern Med. 2003;41(4):409-15.

PMID:
15526523
17.

Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.

Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.

Panminerva Med. 2009 Mar;51(1):17-23.

18.

Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Świętochowska E, Marek B, Kajdaniuk D, Wołkowska-Pokrywa K, Kos-Kudła B.

Endokrynol Pol. 2014;65(1):33-9. doi: 10.5603/EP.2014.0005.

19.

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.

Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.

Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.

PMID:
19574937
20.

Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Wołkowska-Pokrywa K, Szapska B.

Postepy Hig Med Dosw (Online). 2013 May 20;67:433-41. doi: 10.5604/17322693.1050027.

Supplemental Content

Support Center